Meeting
2022 ASCO Annual Meeting
Polymorphism rs4673 and plasma paraoxonase 1 level for prediction and early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer.
Presenter
Dmitry Yu. Gvaldin
National Medical Research Centre for Oncology
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 12077)
DOI
10.1200/JCO.2022.40.16_suppl.12077
Abstract #
12077
Poster Bd #
323
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Fencing in Our Lawns: Where Do We Stand on Boundaries in Medicine?
Speaker: Monica Sheila Chatwal, MD
Videos & Slides
2022 ASCO Annual Meeting
SNP-SNP interactions and a 4-locus model for prediction the risk of anthracycline-mediated cardiotoxicity in patients with breast cancer.
Speaker: Dmitry Yu. Gvaldin
Videos & Slides
2021 ASCO Annual Meeting
Polymorphisms rs4673 and rs28714259 as predictors of anthracycline-mediated cardiotoxicity in patients with breast cancer.
Speaker: Dmitry Yu. Gvaldin
Videos & Slides
2020 ASCO Virtual Scientific Program
Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients: HER2/neu 655 polymorphisms, biochemical and clinical features.
Speaker: Isabel Blancas, MD, PhD